TMEM214

Summary

TMEM214 (transmembrane protein 214, HGNC:25983) is a protein-coding gene on chromosome 2p23.3, encoding Transmembrane protein 214 (Q6NUQ4). Critical mediator, in cooperation with CASP4, of endoplasmic reticulum-stress induced apoptosis.

Predicted to be involved in apoptotic process. Located in several cellular components, including Golgi apparatus; cytoplasmic microtubule; and endoplasmic reticulum.

Source: NCBI Gene 54867 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 111 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_017727

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25983
Approved symbol	TMEM214
Name	transmembrane protein 214
Location	2p23.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20254
Ensembl gene	ENSG00000119777
Ensembl biotype	protein_coding
OMIM	615301
Entrez	54867

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 13 protein_coding, 6 retained_intron, 3 nonsense_mediated_decay

ENST00000238788, ENST00000321326, ENST00000404032, ENST00000425720, ENST00000434544, ENST00000435172, ENST00000444135, ENST00000460665, ENST00000460904, ENST00000469445, ENST00000475258, ENST00000478980, ENST00000495312, ENST00000901050, ENST00000901051, ENST00000901052, ENST00000901053, ENST00000901054, ENST00000901055, ENST00000934286, ENST00000934287, ENST00000934288

RefSeq mRNA: 2 — MANE Select: NM_017727 NM_001083590, NM_017727

CCDS: CCDS42664, CCDS46242

Canonical transcript exons

ENST00000238788 — 17 exons

Exon	Start	End
ENSE00001262189	27037561	27037702
ENSE00001346604	27035594	27035728
ENSE00001606684	27035135	27035285
ENSE00001664738	27035970	27036052
ENSE00001867488	27040711	27041694
ENSE00003462566	27037077	27037178
ENSE00003473517	27040345	27040496
ENSE00003484185	27036705	27036786
ENSE00003488183	27039047	27039164
ENSE00003501274	27039741	27039837
ENSE00003524095	27040030	27040198
ENSE00003567313	27038484	27038532
ENSE00003580027	27038702	27038815
ENSE00003617808	27038146	27038237
ENSE00003635885	27036487	27036592
ENSE00003687812	27034067	27034266
ENSE00003845952	27032965	27033166

Expression profiles

Bgee: expression breadth ubiquitous, 291 present calls, max score 98.25.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 32.2801 / max 223.7794, expressed in 1817 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
19305	31.4583	1817
19306	0.8217	529

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adenohypophysis	UBERON:0002196	98.25	gold quality
pituitary gland	UBERON:0000007	98.09	gold quality
body of pancreas	UBERON:0001150	97.99	gold quality
stromal cell of endometrium	CL:0002255	97.74	gold quality
right lobe of thyroid gland	UBERON:0001119	97.33	gold quality
left lobe of thyroid gland	UBERON:0001120	97.08	gold quality
endocervix	UBERON:0000458	97.06	gold quality
ascending aorta	UBERON:0001496	96.65	gold quality
thoracic aorta	UBERON:0001515	96.61	gold quality
body of uterus	UBERON:0009853	96.52	gold quality
thyroid gland	UBERON:0002046	96.51	gold quality
minor salivary gland	UBERON:0001830	96.48	gold quality
pancreas	UBERON:0001264	96.45	gold quality
saliva-secreting gland	UBERON:0001044	96.29	gold quality
right ovary	UBERON:0002118	96.28	gold quality
body of stomach	UBERON:0001161	96.23	gold quality
left ovary	UBERON:0002119	96.17	gold quality
left coronary artery	UBERON:0001626	96.16	gold quality
cardia of stomach	UBERON:0001162	96.14	gold quality
coronary artery	UBERON:0001621	96.12	gold quality
metanephros cortex	UBERON:0010533	96.09	gold quality
right coronary artery	UBERON:0001625	96.06	gold quality
trachea	UBERON:0003126	96.02	gold quality
left uterine tube	UBERON:0001303	95.96	gold quality
omental fat pad	UBERON:0010414	95.85	gold quality
descending thoracic aorta	UBERON:0002345	95.84	gold quality
right lobe of liver	UBERON:0001114	95.83	gold quality
peritoneum	UBERON:0002358	95.83	gold quality
upper lobe of left lung	UBERON:0008952	95.76	gold quality
aorta	UBERON:0000947	95.75	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.94

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

59 targeting TMEM214, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-6762-3P	99.66	66.94	1188
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-6715B-5P	99.64	69.63	1420
HSA-MIR-9851-3P	99.63	69.68	1110
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-4269	99.55	69.89	1373
HSA-MIR-3616-5P	99.55	67.02	989
HSA-MIR-573	99.55	67.44	955
HSA-MIR-1252-3P	99.55	67.71	2862
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-6165	99.44	67.12	1389
HSA-MIR-5683	99.36	68.59	2083
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-593-5P	99.34	69.50	965
HSA-MIR-5693	99.24	66.67	1106
HSA-MIR-4426	99.17	66.74	1949

Literature-anchored findings (GeneRIF, showing 1)

• TMEM214 is essential for endoplasmic reticulum (ER) stress-induced apoptosis by acting as an anchor for recruitment of procaspase 4 to the ER and its subsequent activation. (PMID:23661706)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	tmem214	ENSDARG00000016968
mus_musculus	Tmem214	ENSMUSG00000038828
rattus_norvegicus	Tmem214	ENSRNOG00000008812
drosophila_melanogaster	Tmem214	FBGN0053129

Protein

Protein identifiers

Transmembrane protein 214 — Q6NUQ4 (reviewed: Q6NUQ4)

All UniProt accessions (5): Q6NUQ4, H7BZI0, H7C008, H7C085, H7C0H8

UniProt curated annotations — full annotation on UniProt →

Function. Critical mediator, in cooperation with CASP4, of endoplasmic reticulum-stress induced apoptosis. Required or the activation of CASP4 following endoplasmic reticulum stress.

Subunit / interactions. Constitutively interacts with CASP4; required for the localization of procaspase 4 to the ER.

Subcellular location. Endoplasmic reticulum membrane.

Similarity. Belongs to the TMEM214 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6NUQ4-1	1	yes
Q6NUQ4-2	2

RefSeq proteins (2): NP_001077059, NP_060197* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019308	TMEM214	Family

Pfam: PF10151

UniProt features (17 total): sequence conflict 5, transmembrane region 2, region of interest 2, glycosylation site 2, initiator methionine 1, chain 1, splice variant 1, sequence variant 1, compositionally biased region 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6NUQ4-F1	78.62	0.49

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Glycosylation sites (2): 269, 307

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 103 (showing top): RRAGTTGT_UNKNOWN, ONKEN_UVEAL_MELANOMA_UP, BILD_E2F3_ONCOGENIC_SIGNATURE, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK, GOCC_CYTOPLASMIC_MICROTUBULE, GOCC_ORGANELLE_SUBCOMPARTMENT, ONDER_CDH1_TARGETS_1_UP, YOSHIMURA_MAPK8_TARGETS_DN, FEVR_CTNNB1_TARGETS_UP, GOCC_SUPRAMOLECULAR_COMPLEX, GOCC_POLYMERIC_CYTOSKELETAL_FIBER, GCNP_SHH_UP_LATE.V1_DN, GOCC_SUPRAMOLECULAR_POLYMER, KMT2D_TARGET_GENES, SNRNP70_TARGET_GENES

GO Biological Process (1): apoptotic process (GO:0006915)

GO Molecular Function (0):

GO Cellular Component (6): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), Golgi apparatus (GO:0005794), cytosol (GO:0005829), cytoplasmic microtubule (GO:0005881), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	4
endomembrane system	2
intracellular membrane-bounded organelle	2
cellular anatomical structure	2
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
microtubule	1

Protein interactions and networks

STRING

1050 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM214	EXD2	Q9NVH0	917
TMEM214	CNOT2	Q9NZN8	902
TMEM214	SEC61B	P38390	853
TMEM214	SEC61G	P38384	684
TMEM214	NPR2	P20594	670
TMEM214	SEC62	Q99442	670
TMEM214	SEC63	Q9UGP8	650
TMEM214	TAFAZZIN	Q16635	649
TMEM214	TMEM38A	Q9H6F2	631
TMEM214	WFS1	O76024	616
TMEM214	SEC61A1	P38378	609
TMEM214	KLHL31	Q9H511	600
TMEM214	CD22	P20273	591
TMEM214	SMIM17	P0DL12	576
TMEM214	NPPC	P23582	548

IntAct

180 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
CARNMT1	NUP42	psi-mi:“MI:0914”(association)	0.640
ABCD4	ABCD4	psi-mi:“MI:0914”(association)	0.640
LYPD3	SCAMP1	psi-mi:“MI:0914”(association)	0.640
FAM234B	ABCD4	psi-mi:“MI:0914”(association)	0.620
KPNB1	POM121C	psi-mi:“MI:0914”(association)	0.530
DLK1	TCAF2	psi-mi:“MI:0914”(association)	0.530
SEMA7A	SGPL1	psi-mi:“MI:0914”(association)	0.530
KIR3DL2	METTL15	psi-mi:“MI:0914”(association)	0.530
CCDC107	PLD2	psi-mi:“MI:0914”(association)	0.530
LYPD6	PLXNB2	psi-mi:“MI:0914”(association)	0.530
ZACN	GPAA1	psi-mi:“MI:0914”(association)	0.530
HMOX2	PRAF2	psi-mi:“MI:0914”(association)	0.530
ASGR2	MT-CO1	psi-mi:“MI:0914”(association)	0.530
STS	GJA1	psi-mi:“MI:0914”(association)	0.530
DPEP1	ILVBL	psi-mi:“MI:0914”(association)	0.530
CSGALNACT2	GOLIM4	psi-mi:“MI:0914”(association)	0.530

BioGRID (241): TMEM214 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), TMEM214 (Affinity Capture-MS), TMEM214 (Proximity Label-MS), TMEM214 (Proximity Label-MS)

ESM2 similar proteins: A0JMW6, A1A535, A1A5P5, A1L1L2, A1L2I9, A2BID5, A4FV45, A7Z033, F1QN74, P56695, Q08CY4, Q0KK59, Q14D04, Q2PW47, Q3UHQ6, Q568Z0, Q5FWU8, Q5JWR5, Q5PQS3, Q5SPP5, Q5U249, Q642P2, Q68F70, Q68Y81, Q6DRL5, Q6GPP1, Q6GQ26, Q6IV68, Q6NUQ4, Q6PI53, Q7SYB2, Q7Z3E5, Q7ZYV9, Q80V62, Q80X82, Q8BL99, Q8BM55, Q8CIM8, Q8JGR7, Q8K1H7

Diamond homologs: A0JMW6, A1L1L2, A1L2I9, A4FV45, Q6NUQ4, Q8BM55

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 204 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RIPK1-mediated regulated necrosis	5	16.0×	2e-03
Transport of Ribonucleoproteins into the Host Nucleus	6	15.0×	9e-04
Nuclear import of Rev protein	6	14.1×	9e-04
Vpr-mediated nuclear import of PICs	6	14.1×	9e-04
IPs transport between nucleus and cytosol	5	13.3×	3e-03
IP3 and IP4 transport between cytosol and nucleus	5	13.3×	3e-03
IP6 and IP7 transport between cytosol and nucleus	5	13.3×	3e-03
Regulation of Glucokinase by Glucokinase Regulatory Protein	5	12.5×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

111 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	84
Likely benign	3
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2713 predictions. Top by Δscore:

Variant	Effect	Δscore
2:27033162:GACCC:G	donor_gain	1.0000
2:27033163:ACCC:A	donor_gain	1.0000
2:27033164:CCC:C	donor_gain	1.0000
2:27033165:CC:C	donor_gain	1.0000
2:27033166:CGTG:C	donor_loss	1.0000
2:27033167:G:GG	donor_gain	1.0000
2:27033167:GTGA:G	donor_loss	1.0000
2:27033168:TGAG:T	donor_loss	1.0000
2:27034252:G:GT	donor_gain	1.0000
2:27034262:AAGCT:A	donor_gain	1.0000
2:27034263:AGCT:A	donor_gain	1.0000
2:27034264:GCT:G	donor_gain	1.0000
2:27034264:GCTG:G	donor_gain	1.0000
2:27034264:GCTGT:G	donor_loss	1.0000
2:27034265:CTG:C	donor_loss	1.0000
2:27034266:TG:T	donor_loss	1.0000
2:27034267:G:GG	donor_gain	1.0000
2:27034268:TGAG:T	donor_loss	1.0000
2:27035283:ATGG:A	donor_loss	1.0000
2:27035285:GGT:G	donor_loss	1.0000
2:27035286:G:GC	donor_loss	1.0000
2:27035286:G:GG	donor_gain	1.0000
2:27035287:T:G	donor_loss	1.0000
2:27035969:GGGGA:G	acceptor_gain	1.0000
2:27036473:ACC:A	acceptor_gain	1.0000
2:27036475:C:A	acceptor_gain	1.0000
2:27036485:A:AG	acceptor_gain	1.0000
2:27036486:G:GG	acceptor_gain	1.0000
2:27036703:A:AG	acceptor_gain	1.0000
2:27036703:AGTGT:A	acceptor_gain	1.0000

AlphaMissense

4456 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:27036544:T:A	W260R	0.997
2:27036544:T:C	W260R	0.997
2:27038200:T:A	W403R	0.997
2:27038200:T:C	W403R	0.997
2:27035229:T:C	L149P	0.996
2:27035217:T:C	L145P	0.995
2:27035985:G:A	G218D	0.995
2:27036583:G:A	G273R	0.995
2:27036583:G:C	G273R	0.995
2:27036707:T:A	W277R	0.995
2:27036707:T:C	W277R	0.995
2:27033048:G:C	W11C	0.993
2:27033048:G:T	W11C	0.993
2:27036587:T:C	L274P	0.993
2:27036759:C:A	A294D	0.993
2:27037659:T:C	L370P	0.993
2:27037666:A:C	R372S	0.993
2:27037666:A:T	R372S	0.993
2:27035151:T:C	L123P	0.992
2:27035984:G:C	G218R	0.992
2:27036546:G:C	W260C	0.992
2:27036546:G:T	W260C	0.992
2:27037596:T:C	L349P	0.992
2:27038188:A:C	S399R	0.992
2:27038190:T:A	S399R	0.992
2:27038190:T:G	S399R	0.992
2:27033046:T:A	W11R	0.991
2:27033046:T:C	W11R	0.991
2:27035600:C:A	P170H	0.991
2:27035991:G:C	R220P	0.991

dbSNP variants (sampled 300 via entrez): RS1000071269 (2:27038304 C>A,G,T), RS1000124712 (2:27038650 G>C), RS1000723320 (2:27032943 C>A,G,T), RS1000901104 (2:27031798 T>A), RS1001126094 (2:27033495 T>TGA), RS1001269739 (2:27032157 C>A,T), RS1001741689 (2:27036828 C>T), RS1001966092 (2:27042116 A>C,G), RS1002062292 (2:27035315 A>G), RS1002138281 (2:27032132 C>A,T), RS1002190768 (2:27032597 G>A), RS1003076759 (2:27037469 C>T), RS1003602953 (2:27040689 A>C), RS1003734966 (2:27033538 C>A), RS1004402098 (2:27042140 G>T)

Disease associations

OMIM: gene MIM:615301 | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST010697_14	Cortical surface area (min-P)	2.000000e-09
GCST010698_75	Subcortical volume (min-P)	2.000000e-13
GCST010699_41	Brain morphology (min-P)	2.000000e-08
GCST010700_38	Cortical thickness (MOSTest)	3.000000e-08
GCST010701_56	Cortical surface area (MOSTest)	4.000000e-16
GCST010702_20	Subcortical volume (MOSTest)	2.000000e-64
GCST010703_76	Brain morphology (MOSTest)	1.000000e-16

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement
EFO:0004840	cortical thickness

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, affects expression, increases expression	4
Ozone	affects expression, affects cotreatment, increases oxidation, increases abundance	3
Cyclosporine	increases expression	3
sodium arsenite	affects cotreatment, decreases expression, increases abundance, increases expression	2
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	2
Acrolein	affects cotreatment, increases oxidation, increases abundance	2
Arsenic	affects cotreatment, decreases expression, increases abundance, affects methylation	2
Cadmium	decreases reaction, increases abundance, increases palmitoylation, decreases expression	2
Smoke	increases expression, decreases expression, increases abundance	2
Cadmium Chloride	increases abundance, increases palmitoylation, decreases expression, decreases reaction	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	decreases sumoylation	1
dicrotophos	increases expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
pirinixic acid	increases activity, increases expression, affects binding	1
bisphenol A	affects cotreatment, increases methylation	1
beta-lapachone	increases expression	1
butyraldehyde	decreases expression	1
2-bromopalmitate	decreases reaction, increases abundance, increases palmitoylation	1
perfluorooctanoic acid	decreases expression	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Caffeine	increases phosphorylation	1
Dietary Carbohydrates	decreases expression	1
Ivermectin	decreases expression	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
Ribonucleotides	affects binding	1

Cellosaurus cell lines

1 cell lines: 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D8E0	Ubigene ARPE-19 TMEM214 KO	Spontaneously immortalized cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms